Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01E PROTEIN KINASE INHIBITORS
L01EX Other protein kinase inhibitors
L01EX14 Entrectinib
D10926 Entrectinib (JAN/USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
Molecular Target Inhibitors
Tropomyocin Receptor Kinase Inhibitors
Entrectinib
D10926 Entrectinib (JAN/USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
429 Miscellaneous
4291 Other Antitumors
D10926 Entrectinib (JAN/USAN/INN)
Drug groups [BR:br08330]
Antineoplastic
DG01918 Tyrosine kinase inhibitor
D10926 Entrectinib
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
D10926 Entrectinib
Metabolizing enzyme inhibitor
DG02852 CYP3A/CYP3A4 inhibitor
D10926 Entrectinib
Target-based classification of drugs [BR:br08310]
Protein kinases
Receptor tyrosine kinases (RTK)
INSR family
ROS1* [HSA_VAR:6098v1]
D10926 Entrectinib (JAN/USAN/INN) <JP/US>
TRK family
NTRK1* (TRKA) [HSA_VAR:4914v1]
D10926 Entrectinib (JAN/USAN/INN) <JP/US>
NTRK2 (TRKB)
D10926 Entrectinib (JAN/USAN/INN) <JP/US>
NTRK3 (TRKC)
D10926 Entrectinib (JAN/USAN/INN) <JP/US>
ALK family
ALK (CD246)
D10926 Entrectinib (JAN/USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D10926
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D10926
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D10926
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D10926
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D10926
Pharmacogenomic biomarkers [br08341.html]
Somatic variations in targeted cancer therapies
D10926